Corvus Pharmaceuticals (CRVS) Retained Earnings (2022 - 2025)
Historic Retained Earnings for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$400.0 million.
- Corvus Pharmaceuticals' Retained Earnings fell 392.31% to -$400.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.0 million, marking a year-over-year decrease of 392.31%. This contributed to the annual value of -$397.0 million for FY2024, which is 1861.06% down from last year.
- According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Retained Earnings is -$400.0 million, which was down 392.31% from -$389.8 million recorded in Q2 2025.
- Corvus Pharmaceuticals' 5-year Retained Earnings high stood at -$274.7 million for Q1 2022, and its period low was -$400.0 million during Q3 2025.
- Its 4-year average for Retained Earnings is -$340.2 million, with a median of -$334.7 million in 2023.
- Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 1861.06% in 2024, then tumbled by 392.31% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Retained Earnings stood at -$307.7 million in 2022, then decreased by 8.78% to -$334.7 million in 2023, then fell by 18.61% to -$397.0 million in 2024, then fell by 0.75% to -$400.0 million in 2025.
- Its last three reported values are -$400.0 million in Q3 2025, -$389.8 million for Q2 2025, and -$381.8 million during Q1 2025.